Phase 2 × Lymphoma, Extranodal NK-T-Cell × Dexamethasone × Clear all Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma
Phase 2 Unknown
50 enrolled
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Phase 2 Unknown
15 enrolled
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Phase 2 Unknown
50 enrolled
VIDL+ASCT
Phase 2 Unknown
27 enrolled
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
Phase 2 Unknown
29 enrolled
Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma
Phase 2 Completed
40 enrolled
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma
Phase 2 Unknown
60 enrolled
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
Phase 2 Completed
55 enrolled 6 charts
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma
Phase 2 Unknown
30 enrolled
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma
Phase 2 Unknown
30 enrolled
Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma
Phase 2 Completed
40 enrolled